Quarterly ResultAug 6, 2026, 08:04 AM
Aligos Therapeutics Q2 2026 Net Loss $1.5M; Advances Pipeline & Partnerships
AI Summary
Aligos Therapeutics reported a significantly reduced net loss of $1.5 million for the second quarter of 2026, compared to $15.9 million in the prior year, driven by $27.778 million in licensing revenue. The company also announced substantial pipeline progress, including Breakthrough Therapy Designation in China for pevifoscorvir sodium and the completion of enrollment for its Phase 2 B-SUPREME study. Additionally, its partner Amoytop received IND approval in China for ALG-170675, triggering a $3 million milestone payment, further strengthening Aligos' financial position through non-dilutive capital.
Key Highlights
- Reported Q2 2026 net loss of $1.5 million, down from $15.9 million in Q2 2025.
- Basic and diluted net loss per common share was $(0.14) for Q2 2026.
- Revenue from licensing agreements totaled $27.778 million for Q2 2026.
- R&D expenses increased to $24.1 million in Q2 2026 from $14.0 million in Q2 2025.
- Cash, cash equivalents and investments were $30.4 million as of June 30, 2026.
- Received a $25 million upfront payment from Amoytop in July 2026 for pevifoscorvir sodium license.
- Expected to receive a $3 million milestone payment in Q3 2026 from Amoytop for ALG-170675 IND approval.
- Pevifoscorvir sodium granted Breakthrough Therapy Designation in China and Phase 2 B-SUPREME study completed enrollment.
Price Impact
More from ALGS